	US 11,986,501 B2
	Treatment methods and compositions
Thomas Y. Ma, Harrisburg, PA (US)
Assigned to UNM RAINFOREST INNOVATIONS, Albuquerque, NM (US)
Appl. No. 17/259,889
Filed by UNM RAINFOREST INNOVATIONS, Albuquerque, NM (US)
PCT Filed Jul. 16, 2019, PCT No. PCT/US2019/041919 § 371(c)(1), (2) Date Jan. 12, 2021, PCT Pub. No. WO2020/018482, PCT Pub. Date Jan. 23, 2020.
Claims priority of provisional application 62/836,968, filed on Apr. 22, 2019.
Claims priority of provisional application 62/698,418, filed on Jul. 16, 2018.
Prior Publication US 2021/0290698 A1, Sep. 23, 2021
Int. Cl. A61K 35/745 (2015.01); A23L 33/135 (2016.01); A61K 35/747 (2015.01); A61P 1/16 (2006.01)

CPC A61K 35/745 (2013.01) [A23L 33/135 (2016.08); A61K 35/747 (2013.01); A61P 1/16 (2018.01)]

14 Claims

1. A method comprising:

administering to a subject having or at risk of having defective intestinal barrier, increased intestinal permeability and/or epithelial tight junction permeability a composition comprising a combination of Lactobacillus acidophilus strain ATCC 4356 and Bifidobacterium bifidum in an amount effective to induce an inhibition or suppression of NF-κB activation in intestinal epithelial cells of the subject.